COMMUNIQUÉS West-GlobeNewswire
-
SAFE - Mise à disposition du Rapport Financier Semestriel 2025
08/12/2025 -
Roche’s Columvi combination shows sustained survival benefit at three-year follow up of pivotal phase III STARGLO study
08/12/2025 -
Zelluna ASA: New share capital registered
08/12/2025 -
Beta Bionics to Pre-Announce Topline Fourth Quarter 2025 Financial Results the Week of January 5, 2026
08/12/2025 -
Abeona Therapeutics® Announces First Patient Treatment with ZEVASKYN® Gene Therapy
08/12/2025 -
BiomX Announces Discontinuation of Phase 2b BX004 Trial Following Internal Review
08/12/2025 -
Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
08/12/2025 -
Wave Life Sciences Announces Positive Interim Data from Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity; Single Dose Resulted in Improvement in Body Composition With Fat Loss Similar to GLP-1 at Three Months Without Muscle Loss
08/12/2025 -
Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks
08/12/2025 -
Kraig Biocraft Laboratories Secures Usage Rights to Strategic Government-Owned Mulberry Gardens to Support Major Spider Silk Production Expansion
08/12/2025 -
Iridex Announces New Thermal Dynamics Study That Strengthens Clinical Foundation and Market Potential of MicroPulse® Technology and Continuous-Wave Laser for Glaucoma Treatment
08/12/2025 -
Orchestra BioMed Announces AVIM Therapy and Virtue SAB Program Presentations at ICI Meeting
08/12/2025 -
AskForHelpToday.ca Launches in New Brunswick, Improving Access to Mental Health Care
08/12/2025 -
AskForHelpToday.ca est lancé au Nouveau-Brunswick, améliorant l’accès aux soins en santé mentale
08/12/2025 -
Virbac : Declaration of the number of shares and voting rights 11/2025
08/12/2025 -
Virbac : Déclaration d'actions et de droits de vote 11/2025
08/12/2025 -
Pan Cancer T Secures EUR 10 Million to Advance First-in-Human Trial of Novel TCR-T Cell Therapy for Triple-Negative Breast Cancer
08/12/2025 -
Geneva College of Longevity Science and DrVibe.ai Launch the GCLS AI Academy for Longevity Sciences
08/12/2025 -
Amphista Therapeutics presents new preclinical data showing the potential of its BRD9 Targeted Glue™, AMX-883, to transform the treatment paradigm for acute myeloid leukaemia
08/12/2025
Pages